Visit healthcare professional site

Request BLC locations near you

Click here

Request BLC locations near you

Click here

See bladder cancer in a different light

Blue Light Cystoscopy
with
Cysview® improves detection
of non-muscle invasive
bladder cancer1,2

Find out more

See bladder cancer in a different light

Blue Light Cystoscopy
 with Cysview® improves detection of non-muscle invasive bladder cancer1,2

Find out more

What is Cysview?

FDA-approved Cysview makes non-muscle invasive bladder cancer (NMIBC) tumors glow bright pink under blue light during Blue Light Cystoscopy (BLC®).3

Cysview solution is placed into the bladder of a bladder cancer patient via a catheter one hour prior to BLC.3 During BLC, Cysview then allows urologists to remove cancer more completely than with standard White Light Cystoscopy (WLC) alone, because BLC with Cysview makes tumors more visible.1,2
Indication: Cysview is an optical imaging agent indicated for use in the cystoscopic detection of carcinoma of the bladder, including carcinoma in situ (CIS), among patients suspected or known to have lesion(s) on the basis of a prior cystoscopy, or in patients undergoing surveillance cystoscopy for carcinoma of the bladder. Cysview is used with the KARL STORZ D-Light C Photodynamic Diagnostic (PDD) system to perform BLC as an adjunct to WLC.3

Find out if Cysview is suitable for you

Who is Cysview® for?

Cysview is for use in people suspected of having, or are known to have, bladder cancer or those undergoing bladder cancer surveillance.3

It should be used during initial or repeat transurethral resection of bladder tumor (TURBT)4 and in surveillance cystoscopies.5

Could Cysview be for me?
Where is Cysview available?

Blue Light Cystoscopy (BLC®) with Cysview® improves non-muscle invasive bladder cancer (NMIBC) tumor detection1,2

See the evidence

What evidence supports Cysview®?

Two different prospective, multicenter clinical studies looked into the effectiveness of BLC with Cysview versus standard White Light Cystoscopy (WLC) alone in detecting bladder cancer in over 300 patients with known or suspected bladder cancer.

They showed that BLC with Cysview improved tumor detection during surgery and in follow-ups:1–3

Study 1:2,3

About the study
A prospective, comparative, within-patient controlled, multicenter, phase III study in the detection of Ta/T1 NMIBC in patients who had previously undergone a cystoscopy and had suspicion of or confirmed NMIBC. (n=286)

Results
During surgery, 16% of patients had additional Ta/T1 tumors only found with BLC with Cysview.

of patients

had additional Ta/T1 tumors only found with BLC with Cysview, during surgery2,3

Study 2:1,3

About the study
A prospective, comparative, within-patient controlled, multicenter, phase III study in the detection of bladder cancer during surveillance. Patients with suspected recurrence at surveillance were sent to the operating room. (n=63)

Results
At follow-up, only BLC with Cysview detected 21% of patients with recurrence
During surgery, 35% of patients with CIS tumors were only found with BLC with Cysview

of patients
with recurrence were only detected with BLC with Cysview at follow-up1,3
of patients
with carcinoma in situ (CIS) tumors were only found with BLC with Cysview during surgery1,3

Study 2:1,3

About the study
A prospective, comparative, within-patient controlled, multicenter, phase III study in the detection of bladder cancer during surveillance. Patients with suspected recurrence at surveillance were sent to the operating room. (n=63)


Results

  • At follow-up, only BLC with Cysview detected 21% of patients with recurrence
  • During surgery, 35% of patients with CIS tumors were only found with BLC with Cysview
See BLC with Cysview guides

Could Blue Light Cystoscopy (BLC®)
with Cysview® be for me?

BLC with Cysview should be considered for patients that are:

At initial transurethral resection of bladder tumor (TURBT) on suspicion of non-muscle invasive bladder cancer (NMIBC)4

  • Having repeat TURBT4

Being checked to assess response to Bacillus Calmette-Guérin (BCG) therapy six weeks after completion4

  • Undergoing surveillance4,5
  • Prior to intravesical therapy when residual disease is suspected, i.e., patient has not previously had BLC with Cysview5
  • With positive cytology and negative White Light Cystoscopy (WLC)4

Cysview may not detect all bladder tumors and is not a replacement for random biopsies

See BLC with Cysview in action
See BLC with Cysview in action

Where is Blue Light Cystoscopy (BLC®)
with Cysview® available?

Cysview is available in many locations throughout the US, with more locations being added regularly.

If you’d like to know where Blue Light Cystoscopy
is available near you, Please reach out.

Contact us for BLC locations

Two types of cystoscopy

White Light Cystoscopy (WLC)

In a standard cystoscopy procedure, the light used is a regular white light – the type used to light a room. White light helps the urologist visually assess the general health of the bladder and find easily visible irregularities to be further evaluated.6

 
 

Blue Light Cystoscopy (BLC®)

When blue light technology and Cysview are available, they are used together with white light in the BLC procedure. The urologist first views the bladder with white light, then switches to blue light to see any bright pink tumor tissue areas that Cysview has caused to fluoresce.6 The urologist then switches between white and blue light to perform the necessary tumor removal.6

See the difference

Bladder images under white and blue light*

Standard WLC

BLC® with Cysview®

*Side-by-side images are the same area of the bladder in white and blue light.

Cysview may not detect all malignant lesions.

Safety information

Any procedure may have some risks. You should consult your urologist regarding the risks and benefits of this procedure.

The most common adverse reactions reported in patients who received Cysview were:3

 
  • Bladder spasm
  • Dysuria
  • Hematuria
  • Bladder pain

The following adverse reactions have been voluntarily reported during post-approval use of Cysview. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure:3

 
  • Anaphylactoid shock
  • Hypersensitivity reactions
  • Bladder pain
  • Cystitis
  • Abnormal urinalysis

References

1. Daneshmand S, Patel S, Lotan Y, et al. Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study. J Urol. 2018;199(5):1158–1165. 2. Stenzl A, Burger M, Fradet Y, et al. Hexaminolevulinate Guided Fluorescence Cystoscopy Reduces Recurrence in Patients with Nonmuscle Invasive Bladder Cancer. J Urol. 2010;184(5):1907–1913. 3. Cysview [prescribing information]. 2019:1–4. 4. Daneshmand S, Schuckman AK, Bochner BH, et al. Hexaminolevulinate Blue-Light Cystoscopy in Non-Muscle-Invasive Bladder Cancer: Review of the Clinical Evidence and Consensus Statement on Appropriate Use in the USA. Nat Rev Urol. 2014;11(10):589–596. 5. Lotan Y, Bivalacqua TJ, Downs T, et al. Blue Light Flexible Cystoscopy with Hexaminolevulinate in Non-Muscle-Invasive Bladder Cancer: Review of the Clinical Evidence and Consensus Statement on Optimal Use in the USA – Update 2018. Nat Rev Urol. 2019;16(6):377–386. 6. Urology Group of Florida. What is Blue Light Cystoscopy? Available at: https://www.urologygroupfl.com/post/what-is-blue-light-cystoscopy. Accessed March 2024.

Important safety information about Cysview® (hexaminolevulinate HCI)

Important safety information about Cysview® (hexaminolevulinate HCI)

Cysview is an optical imaging agent used to detect non-muscle invasive bladder cancer in patients suspected or known to have lesion(s) on the basis of a prior cystoscopy, or in patients undergoing surveillance cystoscopy for bladder cancer. Cysview is not a replacement for random bladder biopsies or other procedures used in the detection of bladder cancer.

Important Risk & Safety Information for Cysview® (hexaminolevulinate HCl)

Cysview is an optical imaging agent used to detect non-muscle invasive bladder cancer in patients suspected or known to have lesion(s) on the basis of a prior cystoscopy, or in patients undergoing surveillance cystoscopy for bladder cancer. Cysview is not a replacement for random bladder biopsies or other procedures used in the detection of bladder cancer. False-positive fluorescence may occur due to inflammation, trauma from past cystoscopies, scar tissue, previous bladder biopsy, and recent Bacillus Calmette-Guérin (BCG) therapy or intravesical chemotherapy.

Anaphylactoid shock, hypersensitivity reactions, bladder pain, bladder inflammation (cystitis), and abnormal urine tests have been reported after administration of Cysview. The most common adverse reactions seen in clinical trials were bladder spasm, trouble urinating, discomfort when urinating, frequent urination, blood in the urine, and bladder pain.

Cysview should not be used in patients with large amounts of blood in their urine, any known allergy to Cysview or any derivative of aminolevulinic acid, or porphyria, a condition that means you already have high levels of porphyrins in your body. No specific drug interaction studies have been performed.

There are no available data on Cysview use in pediatric patients, pregnant women, or nursing mothers.

BLC® and Cysview® are
registered trademarks of Photocure ASA

X-twitter Facebook-f

©2025 Photocure/Cysview. All Rights Reserved.

The information on this website is intended for U.S audiences only.
Residents of Canada, please visit Cysview.ca.

Scroll to Top
Are you a Healthcare Professional?
Yes, I am a U.S Healthcare Professional
No, I am not a U.S Healthcare Professional

You are now leaving the Cysview.com website.

Photocure offers links to third-party websites that may be of interest to our website visitors. If you continue, you will leave the Cysview.com website and be directed to another site. These third-party sites are not under the control of Photocure, and Photocure is not responsible for and has no control over the content of linked third-party websites. Photocure makes no warranties or representations of any kind as to the accuracy, currency, or completeness of any information contained in such websites. Photocure shall not be liable for any damages or injuries of any kind arising from such content or information or reliance thereon. Inclusion of any third-party link on the websites, the content, and/or the services does not imply an endorsement or recommendation by Photocure. You should take precautions when downloading files from all websites to protect your computer from viruses and other destructive programs. If you decide to access linked third-party websites, you do so at your own risk.

 

Please be aware that the security and privacy policies on the third-party sites may be different than Photocure’s policies, so please read third-party privacy and security policies closely. When you visit a third-party site, you will be subject to its terms and policies and no longer be protected by the Cysview.com privacy policy or security practices.

By clicking on the CONTINUE button below, you acknowledge the above statement and will be taken to the linked site. If you want to remain on Cysview.com, select the CANCEL button.

cancel
continue

You are now leaving the Cysview.com website.

Photocure offers links to third-party websites that may be of interest to our website visitors. If you continue, you will leave the Cysview.com website and be directed to another site. These third-party sites are not under the control of Photocure, and Photocure is not responsible for and has no control over the content of linked third-party websites. Photocure makes no warranties or representations of any kind as to the accuracy, currency, or completeness of any information contained in such websites. Photocure shall not be liable for any damages or injuries of any kind arising from such content or information or reliance thereon. Inclusion of any third-party link on the websites, the content, and/or the services does not imply an endorsement or recommendation by Photocure. You should take precautions when downloading files from all websites to protect your computer from viruses and other destructive programs. If you decide to access linked third-party websites, you do so at your own risk.

 

Please be aware that the security and privacy policies on the third-party sites may be different than Photocure’s policies, so please read third-party privacy and security policies closely. When you visit a third-party site, you will be subject to its terms and policies and no longer be protected by the Cysview.com privacy policy or security practices.

By clicking on the CONTINUE button below, you acknowledge the above statement and will be taken to the linked site. If you want to remain on Cysview.com, select the CANCEL button.

cancel
continue

Bacillus Calmette-Guérin (BCG) is an immunotherapy that is put into the bladder directly to treat early-stage bladder cancer (NMIBC).1

Immunotherapies work by causing the body’s immune system to attack the cancer cells.1

Reference: 1. American Cancer Society. Intravesical Therapy for Bladder Cancer. 2022. Available online. Accessed March 2024.

Not all bladder cancer is the same so to help identify it and decide the best treatment option, it is classified according to stage and grade.1

Stage is determined by how far the cancer has gone into the bladder wall and spread, with the stages as follows:1

T0: No tumor     
Ta: Papillary tumor without invading the bladder wall     
TIS (CIS): Carcinoma in situ (non-invasive flat high-grade (G3) cancer)     
T1: Tumor invades the connective tissue under the surface lining     
T2: Tumor invades the muscle layer     
T3: Tumor penetrates the bladder wall and invades the surrounding fat layer   
T4: Tumor invades other organs (i.e., prostate, uterus, vagina, pelvic wall)

Grade is expressed as a number between 1 (low) and 3 (high, i.e., G3); the higher the number, the more the tumor is abnormal. Your urologist, however, may refer to the tumor as either low grade or high grade instead of using a number.1

Reference: 1. Bladder Cancer Advocacy Network. Bladder Cancer Types, Stages and Grades. Available online. Accessed March 2024.

Bladder cancer is classified into two types, depending on the depth of invasion in the bladder wall:1
  • Non-muscle invasive bladder cancer (NMIBC) is in the inner layer of cells and has not gone deeper.1 These cancers are the most common (around 75% of all bladder cancer cases).2
  • Muscle-invasive bladder cancer is when the cancer has penetrated deeper layers of the bladder wall. These cancers are harder to treat and are more likely to spread to other organs.1

    • References: 1. American Cancer Society. What is Bladder Cancer? 2022. Available online. Accessed March 2024. 2. Babjuk M, Burger M, Capoun O, et al. European Association of Urology Guidelines on Non-Muscle-Invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 2022;81(1):75–94.

    TURBT is a surgical procedure where a urologic oncologist removes tumors from the bladder wall. The procedure is performed under general anesthesia in the operating room.1

    Reference: 1. American Cancer Society. Bladder Cancer Surgery. 2019. Available online. Accessed March 2024.